Hamburg

• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca
• A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref … Ended
  2023-509472-42-00 5 Relapsed and/or Refractory Multiple Myeloma
• A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONS … Ended
  2024-512804-20-00 5 Metastatic Colorectal Cancer
• A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart i … Ended
  2024-512986-15-00 4 Sjögren’s Disease
• Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melan … Ended
  2024-516073-74-00 6 Unresectable or metastatic melanoma with a BRAF V600 mutation (inopera
• A study to evaluate the safety and efficacy of mebendazole in combination with low-dose Ara-C in elderly patients with relapsed/refractory a … Ended
  2024-518363-36-00 4 relapsed/refractory acute myeloid leukemia
• A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma Ended
  2025-522054-40-00 4 Previously treated advanced melanoma

Showing 1,081–1,087 of 1,087 trials